Market Overview

5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm

5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm

  • Shibani Malhotra of Nomura is expecting the specialty pharmaceutical and generics "merger frenzy" will continue into 2016.
  • Malhotra argued that companies with access to capital are now "more likely" to pursue deals, be it either friendly or hostile.
  • However, Malhotra cautioned that investor reaction to M&A is "not as uniformly positive" today as it was in 2014.
  • Shibani Malhotra, Nomura's specialty pharmaceuticals and generics industry analyst, initiated coverage of the sector with five Buy-rated recommendations.

    According to Malhotra, the "merger frenzy" seen in the sector is expected to continue into 2016. The analyst noted that the industry faces an "increasingly challenging" macroeconomic environment, characterized by patent expiration, pricing pressures and customer consolidations.

    As such, management teams and boards of directors face "immense" pressure to focus their efforts on "optimal capital allocation."

    The Role Of 'Optimal Capital Allocation'

    Malhotra continued that companies with access to capital are now "more likely" to go on the acquisition hunt and acquire their peers either through friendly or hostile deals.

    However, investor sentiment has shifted as of late and investors are now "more carefully assessing individual deals" and are only beginning to focus on execution and results from deals completed in the past 18 months.

    Related Link: 2 Pharma Stocks To Hide In While Drug Pricing Fears Play Out

    Buy Companies With Favorable Risk-To-Reward Profiles

    Malhotra initiated coverage of the following five names with Buy ratings given their positively skewed risk-to-reward profiles and low-risk value drivers that are not currently reflected in their stock.

    • Allergan PLC (NYSE: AGN)'s management is likely to use capital from the recent sale of its generics business to "generate shareholder value." In addition, the "strength and sustainability" of its underlying business remains "underappreciated."
    • Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s "solid execution" will be a "key driver of value," while M&A activity will "play a role" in further upside.
    • Pacira Pharmaceuticals Inc (NASDAQ: PCRX)'s market opportunity for its Exparel suggests "significant growth potential."
    • Endo International plc - Ordinary Shares (NASDAQ: ENDP) investors "appear to be missing" the true value of the recent Par acquisition, which will become "clearer" when the deal closes.
    • RedHill Biopharma Ltd – ADR (NASDAQ: RDHL) currently has three phase III candidates with a total market opportunity of $10.3 billion. Accordingly, the stock represents an "attractive" long-term investment.

    Image Credit: Public Domain

    Posted-In: Analyst Color Biotech Long Ideas Health Care Top Stories Analyst Ratings Trading Ideas General Best of Benzinga


    Related Articles (ENDP + AGN)

    View Comments and Join the Discussion!

    Latest Ratings

    View the Latest Analytics Ratings
    Don't Miss Any Updates!
    News Directly in Your Inbox
    Subscribe to:
    Benzinga Premarket Activity
    Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
    Market in 5 Minutes
    Everything you need to know about the market - quick & easy.
    Daily Analyst Rating
    A summary of each day’s top rating changes from sell-side analysts on the street.
    Fintech Focus
    A daily collection of all things fintech, interesting developments and market updates.
    Thank You

    Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at